摘要
目的:为了探讨慢性肝病低蛋白血症的治疗方法,观察重组人生长激素对其治疗效果。方法:３９例慢性肝病合并低蛋白血症而无糖尿病、肝脏肿瘤者,随机分为治疗组２０例、对照组１９例,两组年龄、性别、病程及肝功能Ｃｈｉｌｄ－Ｐｕｇｈ分级均无差异;且入选病例血清白蛋白均低于３２ｇ/Ｌ、Ａ/Ｇ比值均小于１．３。治疗组每次肌肉注射４ｕ重组人生长激素,其中前２周隔日１次、后２周每周２次;其他治疗措施与对照组相同。结果:治疗组治疗前、治疗后２周、４周及停药２周、４周时血清白蛋白分别为２９．３±２．７、３２．５±２．９、３５．１±３．２、３６．６±３．４、３５．８±３．３ｇ/Ｌ．而对照组相应为２９．６±２．５、３１．２±２．７、３２．９±３．１、３１．２±３．２、３０．９±３．１ｇ/Ｌ,即治疗组治疗２周时血清白蛋白即升高,４周时明显高于对照组(Ｐ＜０．０５),行程结束后２周、４周治疗组仍维持较高水平,明显高于对照组(Ｐ＜０．０１)。治疗组血清总胆红素、丙氨酸转氨酶均较治疗前降低,停药后维持于低水平,而血清球蛋白、血糖均无变化。结论:重组人生长激素,能纠正慢性肝病患者低蛋白血症并改善肝功能,且停药后仍有持续作用。
ve To investigate the effect of recombinant human growth hormone (rhGH) for chronic; liver disease accompanied by hypoalbuminemia. Methods Thirty-nine patients with chronic liver disease accompanied by hypoalbuminemia without diabetes mellitus and tumor of the liver were randomly divided into treatment group (n=20) and control group (n = 19). There were no statistical differences at entry between the two groups in age, sex, disease duration and Child - Pugh score. Serum levels of albumin in all patients were lower than 32 g/L and albumin -globulin ratios were lower than 1. 3. Patients in treatment group received rhGH intramuscularly for 4 weeks (4IU,every other day in the first 2 weeks and twice a week in the second 2 weeks). The other therapy in treatment group was similar to control group. Results Serum level of albumin in treatment group at the time of pretreatment and 2,4,6,8 weeks after therapy were 29. 3 ± 2. 7,32. 5±2. 9,35. 1 ± 3. 2.36.4 ± 3.4,35.8 ± 3. 3g/L, whereas those in control group were 29. 6 ± 2.5,31.2 ± 2. 7,32. 9 ± 3. 1 ,31. 2 ± 2. 3.30. 9 ± 3. lg/L respectively. The levels of albumin were increased in treatment group at 2 weeks after therapy and obviously higher at 4 weeks after therapy than control group( P <0. 05) ;and at 2,4 weeks after cessation of therapy remained significantly higher in treatment group than control group( P <0. 01). Serum level of total bilirubin.alanine transaminase in treatment group were decreased after therapy compared with pretreatment and remained lower after cessation of therapy. Serum globulin and blood glucose level did not significantly change throughout the study period. Conclusion RhGH can correct the hypoalbuminemia in patient with chronic liver disease and improve the liver function,with the lasting effect after cessation of the therapy.
出处
《河南诊断与治疗杂志》
2002年第2期94-95,共2页
Henan Journal of Diagnosis and Therapy
